The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification of the common underlying molecular alterations. The tumor microenvironment, regulated by inflammatory cells, including cancer cells, stromal tissues, and the surrounding extracellular matrix, has been extensively studied using molecular data. The integration of molecular, immunological, histopathological, and clinical findings has provided clues to uncover predictive biomarkers to enhance responses to novel therapies. Herein, we provide an overview of the current HCC genomic landscape, previously identified gene signatures that are used routinely to predict prognosis, and an immune-specific class of HCC. Since biomarker-driven treatment is still an unmet need in HCC management, translation of these discoveries into clinical practice will lead to personalized therapies and improve patient care, especially in the era of targeted and immunotherapies.
ing the evaluation of somatic mutations and DNA copy number alterations in 363 patients and of deoxyribonucleic acid (DNA) methylation, mRNA expression, microRNA (miRNA) expression, and protein expression in 196 patients, to understand the molecular landscape of HCCs. 4 This study was one of the most comprehensive integrative genomic analyses of HCC to date with clear delineation of the HCC genomic landscape. In parallel with the TCGA project, European researchers in basic, translational, and clinical fields of liver cancer launched the HEPTROMIC project to elucidate the cancer genome and subsequently optimize decisionmaking for liver cancer patients by identifying prognostic genomic determinants and oncogenic drivers. 5 This review, based on results from the projects mentioned above and recent findings, provides an overview of the genetic changes involved in development and progression of HCC. Since HCC is highly resistant to treatment, the translational clinical application of these new findings to identify a subset of patients who might respond to targeted and immunotherapies will be discussed.
LAndScAPE oF GEnoMIc ALtErAtIonS

Somatic mutations and copy number alterations
Somatic mutations occur in the somatic (non-germ) cells and are inheritable. Somatic mutations in tumors are important as the transformation of a normal cell into a cancerous cell occurs sequentially through a few discrete genetic events. 6 Whole-exome sequencing led to the discovery of telomerase reverse transcriptase (TERT ) promoter mutations as the most common somatic mutation (40-65%) detected in HCC. 4, 7, 8 Telomerase is composed of RNA (telomerase RNA component, TERC ) an enzyme, as a rate-limiting component of the complex. TERT is required for telomere synthetase, 9 and patients with a TERT promoter mutation experience telomere shortening, limiting the life span of human hepatocytes and thus, are associated with a higher risk of cirrhosis. 10, 11 TCGA data analysis has shown that patients with the TERT promoter mutation were older, predominantly male, and more likely to be HCV positive than patients without the mutation. HBV insertion in the TERT promoter also occurs in 10-15% of HCCs. 4, 12, 13 The pre-malignant lesion in a cirrhotic liver exhibited the TERT promoter mutation in 6% of low-grade dysplastic nodules, 19% in high-grade dysplastic nodules, and increases dramatically in early HCCs (60%). 14, 15 TERT promoter mutation co-occurring with cyclin-dependent kinase inhibitor 2A (CDKN2A ) silencing by promoter hypermethylation is an early event which behaves as a "gatekeeper" during hepato-carcinogenesis. 4, 16 The genomic landscape using the whole exome-sequencing of 363 HCC cases from the TCGA is shown in Fig. 1 . The significantly mutated tumor suppressor gene, tumor protein P53 (TP53 ) (12-48%), is frequently present in advanced tumors. Other highly mutated suppressor genes were AXIN1 (5-15%) and CTNNB1 (11-37%). Both activate the WNT pathway and promote cell motility and proliferation. 17 The chromatin remodeling genes include AT-rich interaction domain 1A (ARID1A ) (4-17%), ARID2 (3-18%), and BRCA associated protein 1 (BAP1 ) (5%), which regulate transcription of genes. The loss of these tumor suppressor genes causes increased proliferation with poor prognosis. 18 
Epigenetic modification
Epigenetic information includes DNA modifications (including methylation or hydroxylation), histone composition changes, and post-translational modifications (including methylation, acetylation, and phosphorylation), chromatin remodeling, and microRNA and non-coding (nc) RNA (including long nc [lnc] RNA) expression changes. 26 Alterations of the epigenome have been correlated extensively with cancer development, progression, and resistance to therapy. 27, 28 Gene silencing due to promoter hypermethylation is a hallmark of human cancer, as DNA methylation regulates cell differentiation and tumorigenesis. 29 Disproportionally enriched CDKN2A promoter hypermethylation leading to epigenetic silencing was observed in HCV positive tumors, which often co-occurred with TERT promoter and CTNNB1 mutations. 4 In HBV positive HCCs, HBV alters the epigenome via the HBV X (HBx) protein. HBx recruits DNA methyltransferase to the regulatory promoters of the tumor suppressor genes to silence their transcription by hypermethylation. 30 Other downregulated genes due to hypermethylation in HCCs include hedgehog interacting protein (HHIP ), a suppressor of Hedgehog signaling, a pathway important in hepato-carcinogenesis, carbamoyl phosphate synthase I (CPS1 ), a liver-specific rate-limiting enzyme of the urea cycle, 4 adenomatous polyposis coli (APC ), and insulin-like growth factor 2 (IGF2 ). 28 Besides DNA methylation, chromatin modification is another epigenetic mechanism of gene regulation in cancer cells 31 The commonly altered, well-studied chromatin modifiers in HCC are; upregulated enhancer of zeste 2 polycomb repressive complex 2 (EZH2 ), inactivating mutation of ARI-D1A (4-17%), and ARID2 (3-18%). 22, 32, 33 EZH2 , a methyltransferase that mediates gene silencing via the trimethylation of H3K37 shows increased protein expression from the dysplastic nodule to early HCC and is positively correlated with poor survival. 34 ARID1A and ARID2 are proteins that belong to the switch/sucrose non-fermentable (SWI/SNF) ATPase-related chromatin-remodeling complex and have tumor suppressor functions. 35 However, a recent study showed that ARID1A is context-dependent, where the presence of ARID1A expression supports initial HCC development, but loss after tumor development enhances metastatic potential. 36 An interesting study by Hu et al. 37 shows a poor prognosis of ARID1A-deficient HCC mice dependent on increased angiopoietin 2 (Ang2 ) expression. In addition, ARI-D1A deficiency sensitizes tumors to Ang2 blockade by sorafenib treatment, indicating the possibility of ARID1A as a biomarker for anti-angiogenic therapy.
The transcribed genome in the form of RNAs that are not translated into proteins but with regulatory functions, are called ncRNAs. miRNAs are 22-nucleotide RNA molecules that are the most intensively studied ncRNAs. The best example of the recent epigenetic therapy of liver disease is with the miR-122 antagonist, the most frequent one accounting for 70% of the total miRNA. 38 miR-122 regulates genes in the cholesterol metabolism pathway, and a loss of miR-122 correlates with tumor size and invasiveness, making it an attractive therapeutic target for HCC intervention. 39 Other tumorsuppressive miRNAs that are silenced in HCC are miR-26, miR-199a, and miR-200a. [40] [41] [42] LncRNAs comprising 200-300 nucleotides have tissuespecific expression and are transcriptionally regulated by key tumor-suppressors or oncogenes. 43, 44 Functionally, most of the known or predicted lncRNAs have not yet been characterized. Hepatocellular carcinoma up-regulated long noncoding RNA is considered the first lncRNA specifically upregulated in HCC. 45 HOX transcript antisense RNA also negatively regulates miR-218 expression in HCCs through EZH2 targeting miR-218-2 promoter, resulting in oncogenesis. 46 A recent study by Yang et al. 47 identified 917 recurrently deregulated lncRNAs that are correlated with the clinical data in a TCGA cohort and published liver cancer data, and ln-cRNAs HAND2-AS1 were found to be related to metastasis.
The oncomirs that drive the progression of HCC are miR-21, miR-221, miR-222, and miR-224, which are commonly upregulated in HCC. 48, 49 The upregulated levels of miR-221/222
occur as an early event in tumor development and are the most highly expressed miRNAs in HCCs. 50, 51 MoLEcuLAr SuBtYPES
Integrative genomic analysis has facilitated the elucidation of the mutation landscape and pathways involved in the development and progression of HCC. Since HCCs at the same clinical stage differ significantly at the molecular level, the next step is to classify tumors based on the molecular events to improve the clinical management of HCC patients based on biomarkers.
In HCC, many molecular classifications have been reported based on genomic profiling. One pioneering study by Boyault et al. 52 elucidated the molecular diversity of HCC tumors using an unsupervised transcriptome-wide approach to classify many tumors. Boyault's 16-gene signature classified
HCCs into six main subtypes (G1-6), and each subtype showed distinctive characteristics ( Fig. 2 ). G1-3 are characterized by chromosomal instability and lower survival rate compared to that of G4-6. HBV related tumors were classified into the G1 and G2 subgroups and were molecularly distinct from other HCCs.
In contrast to tumors of HBV, HCV infection and alcohol abuse were classified across subgroups G3-6. Apart from HBV infection, low viral DNA copies, AXIN1 mutations, younger age, and high serum levels of α-fetoprotein (AFP)
were observed in the G1 subtype, while high viral DNA copies and frequent local and vascular invasion with TP53 mutations were observed in G2. IGF2 overexpression in G1 and phosphatidylinositol 3-kinase catalytic subunit (PIK3CA ) mutations in G2 were predicted to activate the AKT pathway. The G3 subtype included tumors with the TP53 mutation and CDKN2A leading to cell cycle dysregulation and poor outcomes, while the G4 subtype was composed of mature hepatocytes (non-tumorous liver) without significant genetic alterations. The G5 and G6 subgroups were highly associated with β-catenin activation (70-100%) mainly due to CTNNB1 mutation and the inactivation of E-cadherin, which may be the cause of the local invasion of HCC.
Three common molecular subclasses named as S1, S2, and S3 were identified by Hoshida et al. 53 using the unsupervised clustering-based definition. Briefly, class S1 was associated with a higher risk of early recurrence and invasive/disseminahttps://www.e-jlc.org/ tive phenotype. This class showed a predominance of WNT pathway activation and interaction with transforming growth factor-β (TGF -β) activation. Class S2 tumors were associated with high levels of plasma AFP levels, MYC, and AKT activation signatures, and enrichment of positive EpCAM signatures. The TP53 mutation associated with stepwise malignant transformation was higher in the S1 and S2 classes than in the S3 class, while the β-catenin mutation was more common in well-differentiated S3 tumors. The authors recommended targeted agents such as β-catenin and PI3K inhibitors according to the molecular classifications.
HIStoLoGIcAL SuBtYPES
Based on a comprehensive overview of the molecular features mentioned above, the relationship between HCC molecular features and their phenotypes was determined in resected tumors by combining pathological analysis, gene expression profiling, and gene sequencing. 54 Two distinct HCC mutually exclusive phenotypes, delineated by CTNNB1 (40%) and TP53 (21%) mutations, were noted. CTNNB1 -mutated tumors were large, well differentiated, cholestatic, and had micro-trabecular and pseudo-glandular patterns, and an absence of inflammatory infiltrates. In contrast, TP53 -mutated tumors were poorly differentiated with a compact pattern, multinucleated and pleomorphic cells, and frequent vascular invasion. In addition, TP53 -mutated tumors exhibited PI3K/AKT pathway activation as assessed by phospho-S6 protein in tumor cells and were associated with genes that showed increased cell proliferation, epithelial to mesenchymal transition, and angiogenesis activation.
TP53 also strongly correlated with a novel subtype named "macrotubular-massive" (MTM), which was associated with poor survival, high AFP, vascular invasion, more frequent HBV infected tumor and increased FGF19 amplifications. Higher ANGPT2 mRNA levels, which is known to promote neo-angiogenesis and endothelial sprouting in cooperation of VEGFA , was also observed in MTM-HCC. This subtype was associated with the G3 subgroup (Fig. 2) .
Another phenotype scirrhous HCC subtype, defined by marked stromal fibrosis, showed CK19 expression and the upregulation of progenitor/cancer stem cell genes (CD24 , KRT19, THY1, and CD133), and epithelial-to-mesenchymal transition activation (TGF -β, VIM ). The "Steatohepatitis " Based on the integrative analysis, highly reproducible HCC subtypes were developed (Fig. 2) . 53, 54 Chromosomal instability, the G1-3 subgroups, S1, and S2 subtypes, and the proliferative subtypes are collectively called the "proliferative" subtype and are associated with more progressive tumors. In contrast, chromosomal stability, the G4-6 subgroups, and the S3 subtypes are called the "non-proliferative" subtype, with hepatic physiology resembling that of healthy individuals.
cLInIcAL APPLIcAtIon For PrEcISIon cAncEr MEdIcInE
Genomic profiling enables the management of treatment for cancer patients by selecting appropriate targeted therapy based on tumor genotypes or other features. The "oncogene addiction theory" postulates that some cancers depend on one or a few genes for the maintenance of the malignant phenotype. 55 The successful translation of this principle in cancer management is evidenced by the treatment of HER-2/NEU positive breast cancer patients with the trastuzumab antibody targeting the receptor tyrosine kinase, 56 and in BRAF V600E mutated melanoma patients treated with the vemurafenib antibody. 57 An appropriate biomarker should be established for the accurate identification of patient tumors expressing oncogene addiction to achieve survival benefits after selective inhibition. Challenges lie in developing targeted therapies for HCC, as the frequently mutated genes such as TERT, TP53, CTNNB1 , and MYC are undruggable. Therefore, patients and clinicians had a long wait until promising results were reported for newly developed kinase inhibitors and immunotherapies. Despite significant improvements in the management of advanced HCC and promising results with novel therapies, a considerable number of patients (>60%) do not respond to these novel therapies. 58, 59 The uncertainty of the combination of immune cells forming the immune microen-vironment and the extent of intra-tumoral heterogeneity in HCC are the limiting factors for deriving predictive biomarkers to enhance responses to these novel therapies.
With more options for sequential systemic treatments for advanced HCC, clinicians have to choose between sorafenib and lenvatinib as the first-line treatment and between regorafenib and nivolumab as the second-line treatment after sorafenib. Biomarkers research is a paramount research area, and the next section discusses predictive gene signatures and biomarkers discovered using the extensive exploratory biomarker analysis of DNA, RNA, and protein levels to identify a subset of patients who are likely to benefit from specific targeted therapies.
Immune features of HCCs
Sia et al. 60 identified an immune specific subtype of HCC by analyzing gene expression data from 228 HCCs using a non-negative matrix factorization algorithm to distinguish tumor, stromal, and immune cell signatures and validated these in 728 tumor samples. Using the gene signature, "immune class" that comprises 24% of total patients were identified, and this group captured the 1) signatures of immune cells (i.e., T-cells, cytotoxic cells, tertiary lymphoid structures [TLS ], and macrophages), 2) signatures of responses to immune checkpoint therapy, 3) interferon (IFN) signaling, and 4) Hoshida's S1 class. Immunophenotyping of tumor sections also showed high PD-1 and PD-L1 protein expression and significantly enriched presence of TLS in the "immune class" (Fig. 3) .
The infiltration of immune cells in tumors has a positive
or negative effect on patient prognosis depending on tumor stroma modification. 61 Immune cells can destroy the homeostasis between cell proliferation and cell death through interactions with the extracellular matrix and fibroblasts, leading to epithelial-mesenchymal transition, invasion, and metastasis. The "immune class" was sub-classified into two classes.
The first class, called the "active immune response" subtype, was observed in 67% of the "immune class", and was characterized by a lack of activated stroma. The significant enrichment of T-cells and active interferon signatures, including https://www.e-jlc.org/ adaptive immune response genes such as granzyme B (GZMB ), IFN -γ, CD8A , and IFN signatures predictive of pembrolizumab response, were the hallmarks of this subtype.
The presence of activated stroma was observed in the "exhausted immune response" subtype.
Conversely, this subtype was characterized by tumor-pro-moting signals such as the T-cell exhaustion signature, defined by TGF -β-regulated network activity and M2 macrophages. TGF -β regulates tumor-stroma interaction, angiogenesis, and metastasis. Immunosuppressive factors such as galectin (LGALS1 ), C-X-C motif chemokine ligand 12 (CXCL12 ), and C-C motif chemokine ligand 2 (CCL2 ) Figure 3 . Classification of hepatocellular carcinomas based on immune classes. Immune classes are characterized by high immune tumor infiltration levels and are classified into two subgroups. The "active immune" subgroup has markers for adaptive T-cell responses and has molecular traits responsive to immunotherapies, while the "exhausted immune group" has stromal and TGF-β activation. HCC, hepatocellular carcinoma; CCL4, C-C motif chemokine ligand 4; CTNNB1, catenin beta 1; IFN-γ, interferon-gamma; GZMB, granzyme B; PD-1, programmed cell death 1; PD-L1, program cell death 1 ligand 1; PRF, perforin 1; PTK2, protein tyrosine kinase 2; TGF-β, transforming growth factor-beta 1; TLS, tertiary lymphoid structures. Adapted from reference 60 and reference 62 with permission.
were also observed in this subtype while essential NK cell activators such as GZMB, IFN-γ, T-Box 21 (TBX21 ), and NK-G2D were significantly downregulated. The tumor recurrence rate was higher in the "exhausted immune response" group than in the "active immune response" group. Although this study is not directly applicable to clinics, immune classifiers could help identify patients who might respond better to immunotherapies and those who need additional molecular inhibitors such as the TGF-β inhibitor.
In another study, the authors analyzed the immune microenvironment of 919 regions from 158 HCCs. This study showed that in addition to the currently known histopathological and molecular subtypes, the classification of immune microenvironments into immune-high, immune-mid, and immune-low had a prognostic impact depending on the subtypes. 62 Intratumor heterogeneity among the immune sub- 
Biomarkers associated with responses to regorafenib
The most comprehensive analysis for predicting the response to regorafenib was performed using plasma and archival tumor samples from the RESORCE trial for protein, miRNA, and genetic biomarkers. 63 Mutations in CTNNB1 were observed only in progressors, but not in responders, while VEGFA amplification based on tissue analysis was observed in responders but not in progressors. This is an important finding as VEGFA is the ligand for VEGFR, a target for regorafenib. Increased baseline plasma levels of AFP and c-MET were independent of regorafenib treatment responses, but instead five newly identified plasma proteins (ANG-1 , cystatin B , LAP TGF -β1, LOX-1 , and MIP-1 α) showed significant associations with increased overall survival for regorafenib treatment. Except for ANG-1 , which is associated with angiogenesis and tumor progression, other proteins such as LAP TGF -β1 are known to be precursors to TGF -β and MIP-1α, which induce immune cell infiltration and are not direct targets of regorafenib indicating indirect communication between the biomarkers and regorafenib. 64 
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